The molecular landscape for diffuse large B-cell lymphoma has become more intricate in recent years, highlighting unique genomic subtypes with implications ranging from diagnosis to prognosis to personalized treatment. Join expert DLBCL faculty as they review guideline recommendations and therapeutic implications for the biomarkers included in the diagnostic workup of DLBCL, as well as strategies to incorporate biomarker-driven therapy to optimize patient outcomes.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/biomarkers-dlbcl-current-implications-diagnosis-prognosis-treatment
- Start Date: 2024-10-31 05:00:00
- End Date: 2024-10-31 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Pfizer (Any division) - Amount: 45000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest